Six out of nine patients in the phase-II part of the ProTrans-1 study have completed treatment

Booking.com

NextCell Pharma AB (NextCell) announces that six out of the nine patients included in ProTrans-1, the trial with the drug candidate ProTrans, now have completed treatment and left the study.
Earlier this week, the last of the three patients in the so-called medium-dose-cohort visited for their 12-month follow-up, the final part of the trial, which means that all three now have completed their part of the trial. In early March, the three patients in the low-dose cohort had already completed the trial. This means that six out of nine patients in the phase II part have now successfully

Source: Six out of nine patients in the phase-II part of the ProTrans-1 study have completed treatment

Booking.com
Booking.com

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.